Atara Biotherapeutics (ATRA) Depreciation & Amortization (CF) (2013 - 2026)

Atara Biotherapeutics' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $29000.0 for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 98.38% year-over-year to $29000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $350000.0 (down 93.58% YoY) and the FY2025 annual result came in at $2.1 million, down 58.11% from the prior year.
• Depreciation & Amortization (CF) was $29000.0 for Q1 2026 at Atara Biotherapeutics, down from $49000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.8 million in Q1 2025 and bottomed at $29000.0 in Q1 2026.
• A 5-year average of $1.0 million and a median of $1.2 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2025 — Depreciation & Amortization (CF) increased 29.04% — and 2026, when it slumped 98.38%.
• Atara Biotherapeutics' Depreciation & Amortization (CF) stood at $1.3 million in 2022, then retreated by 3.98% to $1.2 million in 2023, then fell by 8.71% to $1.1 million in 2024, then tumbled by 95.55% to $49000.0 in 2025, then tumbled by 40.82% to $29000.0 in 2026.
• Business Quant data shows ATRA's Depreciation & Amortization (CF) at $29000.0 in Q1 2026, $49000.0 in Q4 2025, and $36000.0 in Q3 2025.